| Treatment strategy | Average cost per patient INT$ (95% CI)¶ | Blind (95% CI) | Default (95% CI) | Fail (95% CI) | Relapse (95% CI) | Acquire INH monoresistance (95% CI) | Acquire MDR (95% CI) | TB deaths (95% CI) |
| 5% INH monoresistant TB, 1% MDR-TB+ | ||||||||
| Standard | 4697 (4600–4794) | 21 (21–21) | 9037 (8979–9095) | 1295 (1290–1300) | 3917 (3908–3926) | 344 (342–346) | 407 (404–410) | 5207 (5177–5237) |
| EMB initial | 4687 (4592–4782) | 251 (247–255) | 9053 (8995–9111) | 1209 (1204–1214) | 3905 (3896–3914) | 179 (178–180) | 221 (219–223) | 5138 (5108–5168) |
| Str retreat | 4697 (4600–4794) | 21 (21–21) | 9029 (8971–9087) | 1258 (1253–1263) | 3889 (3880–3898) | 332 (330–334) | 375 (372–378) | 5194 (5164–5224) |
| MDR failures | 4732 (4635–4829) | 22 (22–22) | 9076 (9018–9134) | 1070 (1066–1074) | 3895 (3886–3904) | 344 (342–346) | 401 (334–342) | 5132 (5102–5162) |
| 15% INH monoresistant TB, 1% MDR-TB+ | ||||||||
| Standard | 4771 (4668–4874) | 24 (24–24) | 9161 (9103–9220) | 1780 (1765–1795) | 4618 (4606–4630) | 308 (306–310) | 781 (772–790) | 5419 (5389–5449) |
| EMB initial | 4756 (4659–4853) | 254 (250–258) | 9194 (9135–9253) | 1634 (1627–1647) | 4604 (4593–4615) | 160 (159–161) | 434 (429–439) | 5291 (5261–5321) |
| Str retreat | 4763 (4660–4866) | 24 (24–24) | 9143 (9085–9201) | 1697 (1685–1712) | 4559 (4548–4570) | 297 (295–299) | 720 (711–729) | 5392 (5362–5422) |
| MDR failures | 4814 (4711–4917) | 25 (24–24) | 9218 (9160–9226) | 1467 (1456–1478) | 4589 (4577–4601) | 307 (305–309) | 775 (766–784) | 5310 (5280–5340) |
| 5% INH monoresistant TB, 10% MDR-TB+ | ||||||||
| Standard | 5009 (4910–5108) | 36 (36–36) | 8469 (8416–8522) | 6856 (6845–6867) | 4159 (4150–4168) | 311 (309–313) | 387 (384–390) | 9593 (9565–9621) |
| EMB initial | 5000 (4900–5100) | 266 (262–270) | 8484 (8431–8537) | 6774 (6764–6784) | 4144 (4135–4153) | 161 (160–162) | 210 (208–212) | 9526 (5261–5321) |
| Str retreat | 5009 (4909–5109) | 36 (35–37) | 8461 (8408–8514) | 6820 (6809–6831) | 4127 (4118–4136) | 300 (298–302) | 357 (354–360) | 9580 (9552–9608) |
| MDR failures | 5157 (5057–5257) | 38 (37–39) | 8803 (8750–8856) | 5252 (5245–5259) | 4020 (4011–4029) | 311 (309–313) | 382 (379–385) | 8963 (8935–8991) |
| 15% INH monoresistant TB, 10% MDR-TB+ | ||||||||
| Standard | 5084 (4985–5183) | 40 (39–41) | 8593 (8540–8646) | 7341 (7324–7358) | 4860 (4849–4871) | 275 (273–277) | 761 (752–770) | 9805 (9777–9833) |
| EMB initial | 5069 (4970–5168) | 269 (265–273) | 8626 (8573–8679) | 7199 (7183–7215) | 4843 (4832–4854) | 142 (141–143) | 424 (419–429) | 9680 (9657–9708) |
| Str retreat | 5075 (4976–5174) | 39 (38–40) | 8575 (8522–8628) | 7259 (7242–7276) | 4797 (4786–4808) | 265 (263–267) | 702 (693–711) | 9778 (9750–9806) |
| MDR failures | 5240 (5141–5339) | 41 (40–42) | 8945 (8892–8998) | 5649 (5637–5661) | 4714 (4703–4725) | 274 (272–276) | 755 (746–764) | 9141 (9114–9168) |
INT$: international US dollars; EMB: ethambutol; Str retreat: strengthened retreatment; MDR failures: MDR treatment for failures. #: model results were based on hypothetical cohorts of 100 000 smear-positive TB patients. 95% confidence intervals are based on the probability sensitivity analyses results of 10 000 Monte Carlo simulations. ¶: Ecuador treatment costs were used for estimating the average cost. +: n=100 000.